



Marksans Pharma Ltd.

Date: 15th June, 2021

BSE Limited
Corporate Relation Department
Phiroze Jeejeeboi Towers,
Dalal Street,
Mumbai - 400001.
Scrip Code: 524404

National Stock Exchange of India Limited
Listing Department
Exchange Plaza, C-1, Block-G,
Bandra-Kurla Complex,
Bandra (East), Mumbai - 400051.
Symbol: MARKSANS

Dear Sir,

Re: Outcome of Board Meeting

This is further to our intimation dated 10th June, 2021 and in accordance with Regulation 30 of SEBI (LODR) Regulations, 2015, please note that the Board of Directors at its meeting held today, i.e., 15th June, 2021, has considered and approved, subject to approval of the Shareholders of the Company, the following issue of convertible warrants on preferential basis in accordance with the provisions of Chapter V of SEBI (ICDR) Regulations, 2018, the Companies Act, 2013 and other applicable laws:

- (a) 10,00,000 convertible warrants to Mr. Mark Saldanha (Promoter of the Company) at a price of INR 74.00 per warrant, being the price not less than the price determined in accordance with Chapter V of SEBI (ICDR) Regulations, 2018; and
- (b) 4,93,24,324 convertible warrants to OrbiMed Asia IV Mauritius FVCI Limited at a price of INR 74.00 per warrant, being the price not less than the price determined in accordance with Chapter V of SEBI (ICDR) Regulations, 2018.

The Board of Directors of the Company at the same meeting has also decided:

- (a) Amendment of the Articles of Association of the Company; and
- (b) Convening of an Extra-ordinary General Meeting on 9th July, 2021 for obtaining shareholders' approval in respect of the above issue of convertible warrants.

The details as required under SEBI (LODR) Regulations, 2015 read with SEBI Circular No. CIR/CFD/CMD/4/2015 dated September 9, 2015 with respect to the proposed preferential issue are given in **Annexure – A**.

The meeting of the Board of Directors commenced at 11:00 AM and concluded at 11:40 AM.

You are requested to note the above in your records.

Thanking You,

For Marksans Pharma Limited

Harshavardhan Panigrahi
Company Secretary

Enclosed as above

Marksans Pharma Ltd.

11th Floor, "GRANDEUR", Opp. Gundecha Symphony, Veera Desai Extension Road, Oshiwara,
Andheri (W), Mumbai - 400 053 • Tel.: +91 22 4001 2000 • E-mail: info@marksanspharma.com
www.marksanspharma.com



Marksans Pharma Ltd.

Annexure - A Details regarding Preferential Allotment

Sr. No.	Particulars	Details
1	Type of securities proposed to be issued (viz. Equity shares, convertibles etc.)	Convertible Warrants with right exercisable by the warrant holder to subscribe to one equity share of Re. 1/- face value per warrant.
2	Type of issuance (further public offering, rights issue, depository receipts (ADR/GDR), qualified institutions placement, preferential allotment etc.)	Preferential Issue in accordance with Chapter V of SEBI (ICDR) Regulations, 2018.
3	Total number of securities proposed to be issued or the total amount for which the securities will be issued (approximately)	(a) 10,00,000 convertible warrants each carrying a right exercisable by the warrant holder to subscribe to one equity share of face value of Re 1/- each per warrant. (b) 4,93,24,324 convertible warrants each carrying a right exercisable by the warrant holder to subscribe to one equity share of face value of Re 1/- each per warrant.
	Additional details in case of preferential issue	
4	Name of investors	(a) Mr. Mark Saldanha (Promoter) (10,00,000 warrants) (b) OrbiMed Asia IV Mauritius FVCI Limited (4,93,24,324 warrants)
5	Number of Investors	2
6	Post allotment of securities- outcome of the subscription:	(a) Issue price of each Warrant: Rs 74. (25% of the issue price of each Warrant will be paid upfront for allotment of the Warrant. The remaining 75% of the issue price of each Warrant shall be payable at the time of conversion of the said Warrant into equity share of the Company.) (b) Conversion ratio of each Warrant: 1:1. (c) Each Warrant can be converted into one equity share of the Company at any time within eighteen months from the date of allotment of Warrants.
7	In case of convertibles - intimation on conversion of securities or on lapse of the tenure of the instrument	Will be intimated at the time of conversion

Marksans Pharma Ltd.

11th Floor, "GRANDEUR", Opp. Gundecha Symphony, Veera Desai Extension Road, Oshiwara
Andheri (W), Mumbai - 400 053 • Tel.: +91 22 4001 2000 • E-mail: info@marksanspharma.com
www.marksanspharma.com